Sign In
Buy NTRA
$272.89
+2.94 (+1.09%)
At Close: Jul 13, 2026
NTRA's Signatera Gains EU IVDR Certification for Multiple Cancers
11:01am, Friday, 10'th Jul 2026
Natera's Signatera became the first personalized MRD test for solid tumors to earn EU IVDR certification, supporting broader expansion across Europe.
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
09:56am, Thursday, 09'th Jul 2026
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
Natera Announces IVDR Certification for Signatera™ Across Multiple Cancers
06:00am, Thursday, 09'th Jul 2026
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that Signatera has received certification as a Class C device unde
Signatera™ MRD Test Predicted Overall Survival Benefit from Chemotherapy in Resected Metastatic Colorectal Cancer
06:00am, Monday, 06'th Jul 2026
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the publication of new data in JAMA Oncology, evaluating the utili
NTRA & Aveta Partner to Advance MRD-Guided Trial in Head & Neck Cancer
12:01pm, Wednesday, 01'st Jul 2026
Natera's Aveta partnership brings Signatera into a global Phase 3 head and neck cancer trial to assess MRD and treatment response.
Natera, Aveta partner on late-stage head and neck cancer trial
06:55am, Monday, 29'th Jun 2026
Genetic testing firm Natera and cancer drug developer Aveta Biomics said on Monday they have partnered on a late-stage study of an experimental therapy for head and neck cancer, in a bid to impr
AUSTIN, Texas & BEDFORD, Mass.--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, and Aveta Biomics, Inc., a clinical-stage immuno-oncology company
NTRA's Signatera Secures PMDA Approval for MRD Testing in CRC in Japan
10:55am, Thursday, 25'th Jun 2026
Natera's Signatera gains Japan PMDA approval for CRC, marking the country's first approved MRD test and advancing its global expansion.
Natera (NTRA) Stock Jumps 10.7%: Will It Continue to Soar?
09:06am, Thursday, 25'th Jun 2026
Natera (NTRA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in t
Natera and Eledon Announce Strategic Partnership for Prospera™ Monitoring in Planned Phase 3 Kidney Transplant Trial
07:00am, Thursday, 25'th Jun 2026
AUSTIN, Texas & IRVINE, Calif.--(BUSINESS WIRE)--Natera, Inc. (Nasdaq: NTRA), a global leader in cell-free DNA and precision medicine, and Eledon Pharmaceuticals, Inc. (Nasdaq: ELDN), a clinical stage
Natera Secures Landmark Japan Nod For Signatera In Colorectal Cancer
02:14pm, Wednesday, 24'th Jun 2026
Natera Inc. (NASDAQ:NTRA) said Japan's Ministry of Health, Labour and Welfare approved its Signatera molecular residual disease (MRD) test for patients with colorectal cancer in the adjuvant setting,
Signatera™ Receives Regulatory Approval in Japan for Colorectal Cancer
05:00am, Wednesday, 24'th Jun 2026
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that Signatera has received regulatory approval from Japan's Pharm
Signatera™ Receives Regulatory Approval in Japan for Colorectal Cancer
03:00am, Wednesday, 24'th Jun 2026
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that Signatera has received regulatory approval from Japan's Pharm
EXEL Down on Colorectal Cancer Study Data on Zanzalintinib
03:26pm, Tuesday, 23'rd Jun 2026
Exelixis falls after STELLAR-303 misses statistical significance in overall survival for a key colorectal cancer subgroup, raising approval uncertainty.
NCCN Recommends ctDNA-MRD Testing Using Signatera™ Technology in Landmark Bladder Cancer Guideline Update
06:00am, Tuesday, 23'rd Jun 2026
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that the National Comprehensive Cancer Network® (NCCN®) has upda
